Related references
Note: Only part of the references are listed.Prognostic factors for the feasibility of chemotherapy and the Geriatric Prognostic Index (GPI) as risk profile for mortality before chemotherapy in the elderly
Ab A. Aaldriks et al.
ACTA ONCOLOGICA (2016)
Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial
Yazhou He et al.
TRIALS (2015)
Impact of comorbidity on outcome of older breast cancer patients: a FOCUS cohort study
Mandy Kiderlen et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer
Z. Daher Abdi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
Dan Lu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Sharon H. Giordano et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2-Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Ann H. Partridge et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy
Mihaela A. Popa et al.
JOURNAL OF GERIATRIC ONCOLOGY (2014)
Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030)
S. G. Louie et al.
BRITISH JOURNAL OF CANCER (2013)
Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study
F. Mueller et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
An Integrated Multiple-Analyte Pharmacokinetic Model to Characterize Trastuzumab Emtansine (T-DM1) Clearance Pathways and to Evaluate Reduced Pharmacokinetic Sampling in Patients with HER2-Positive Metastatic Breast Cancer
Dan Lu et al.
CLINICAL PHARMACOKINETICS (2013)
Screening methods for geriatric frailty
Simone Mathoulin-Pelissier et al.
LANCET ONCOLOGY (2013)
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
David Cunningham et al.
LANCET ONCOLOGY (2013)
Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer
Yeon-Joo Kim et al.
RADIATION ONCOLOGY (2013)
Covariate Pharmacokinetic Model Building in Oncology and its Potential Clinical Relevance
Markus Joerger
AAPS JOURNAL (2012)
Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer
H. J. Chang et al.
ANNALS OF ONCOLOGY (2012)
Evaluation of glomerular filtration rate estimation by Cockcroft-Gault, Jelliffe, Wright and Modification of Diet in Renal Disease (MDRD) formulae in oncology patients
N. L. Ainsworth et al.
ANNALS OF ONCOLOGY (2012)
Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy
C. Twelves et al.
ANNALS OF ONCOLOGY (2012)
Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C14-erythromycin breath test and the antipyrine clearance test
M. Michael et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Evaluation of a Pharmacology-Driven Dosing Algorithm of 3-Weekly Paclitaxel Using Therapeutic Drug Monitoring
Markus Joerger et al.
CLINICAL PHARMACOKINETICS (2012)
Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2-Targeted Antibody-Drug Conjugate, in Patients With HER2-Positive Metastatic Breast Cancer
Manish Gupta et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review
Marije E. Hamaker et al.
LANCET ONCOLOGY (2012)
Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)
Laura Biganzoli et al.
LANCET ONCOLOGY (2012)
Mass Balance Study of [14C]Eribulin in Patients with Advanced Solid Tumors
Anne-Charlotte Dubbelman et al.
DRUG METABOLISM AND DISPOSITION (2012)
Effect of Age on Systemic Exposure and Haematological Toxicity of Carboplatin in Advanced Non-Small Cell Lung Cancer Patients
Matilde Merino-Sanjuan et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2011)
Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer
Maarten J. Deenen et al.
CLINICAL CANCER RESEARCH (2011)
Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors Focus on 4-Anilinoquinazolines
Matthias Scheffler et al.
CLINICAL PHARMACOKINETICS (2011)
Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors Focus on Pyrimidines, Pyridines and Pyrroles
Paola Di Gion et al.
CLINICAL PHARMACOKINETICS (2011)
Population Pharmacokinetic-Pharmacodynamic Analysis of Trastuzumab-Associated Cardiotoxicity
J. G. C. van Hasselt et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Examining the Evidence: A Systematic Review of the Inclusion and Analysis of Older Adults in Randomized Controlled Trials
Donna M. Zulman et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2011)
Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors
BingHe Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
Matthew T. Seymour et al.
LANCET (2011)
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)
R. Colomer et al.
ANNALS OF ONCOLOGY (2010)
Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients
E. Bastiaannet et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Clinical Impact of Intensified 5-Fluorouracil-Based Chemotherapy Using a Prospective Pharmacokinetically-Guided Dosing Approach: Comparative Study in Elderly and Non-Elderly Patients with Metastatic Colorectal Cancer
J. Duffour et al.
JOURNAL OF CHEMOTHERAPY (2010)
Assessment and treatment of elderly patients with cancer
Lodovico Balducci et al.
SURGICAL ONCOLOGY-OXFORD (2010)
Pharmacokinetics and drug metabolism in the elderly
Ulrich Klotz
DRUG METABOLISM REVIEWS (2009)
Impact of Diabetes Mellitus on Complications and Outcomes of Adjuvant Chemotherapy in Older Patients With Breast Cancer
Tomasz P. Srokowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation
Benjamin D. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of cancer and leukemia group B protocol 9840
Andrew D. Seidman et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: A study by the EORTC-PAMM-NDDG
Markus Joerger et al.
CLINICAL PHARMACOKINETICS (2007)
Pharmacokinetics and toxicity of weekly docetaxel in older patients
Arti Hurria et al.
CLINICAL CANCER RESEARCH (2006)
Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer
Mark Wong et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and leukemia group B (CALGB 9762)
SM Lichtman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of paclitaxel in patients with solid tumors
M Joerger et al.
CLINICAL CANCER RESEARCH (2006)
The absolute bioavailability of oral vinorelbine in patients with solid tumors
RM Lush et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Capecitabine as adjuvant treatment for stage III colon cancer
C Twelves et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women
E Bajetta et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly
AJ ten Tije et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Optimising treatment of elderly patients with ovarian cancer - Improving their enrolment in clinical trials
J Villella et al.
DRUGS & AGING (2005)
Treating Individuals 1 - External validity of randomised controlled trials: To whom do the results of this trial apply?'
PM Rothwell
LANCET (2005)
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer
P Fumoleau et al.
EUROPEAN JOURNAL OF CANCER (2004)
Comparison of pharmacokinetics and pharmacodynamics of docetaxel and cisplatin in elderly and non-elderly patients: Why is toxicity increased in elderly patients?
H Minami et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Population pharmacokinetics of weekly docetaxel in patients with advanced cancer
KA Slaviero et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Participation in cancer clinical trials - Race-, sex-, and age-based disparities
VH Murthy et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Drug therapy in the elderly
M Turnheim
EXPERIMENTAL GERONTOLOGY (2004)
Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial
C Gridelli et al.
EUROPEAN JOURNAL OF CANCER (2004)
Lack of contribution of dihydrofluorouracil and α-fluoro-β-alanine to the cytotoxicity of 5′-deoxy-5-fluorouridine on human keratinocytes
JL Fischel et al.
ANTI-CANCER DRUGS (2004)
Participation of patients 65 years of age or older in cancer clinical trials
JH Lewis et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients
R Gieschke et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer
CH Smorenburg et al.
EUROPEAN JOURNAL OF CANCER (2003)
Pharmacological factors influencing anticancer drug selection in the elderly
V John et al.
DRUGS & AGING (2003)
A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine
P Variol et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2002)
A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer
A Gauvin et al.
ANTI-CANCER DRUGS (2002)
Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials
L Nguyen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Population pharmacokinetic analysis of the major metabolites of capecitabine
R Gieschke et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2002)
Mechanism-based pharmacokinetic model for paclitaxel
A Henningsson et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel
R Bruno et al.
INVESTIGATIONAL NEW DRUGS (2001)
Renal tolerance to cisplatin in patients 70 years and older
A Cubillo et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2001)
Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older
R Yancik et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors
M Marty et al.
ANNALS OF ONCOLOGY (2001)
Oral vinorelbine: Feasibility and safety profile
A Depierre et al.
ANNALS OF ONCOLOGY (2001)
Liver function and phase I drug metabolism in the elderly - A paradox
DL Schmucker
DRUGS & AGING (2001)
Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age
Y Nakamura et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol
N Yamamoto et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer
EC Dees et al.
CANCER INVESTIGATION (2000)
Share Paper
